Market capitalization | $266.77m |
Enterprise Value | $191.14m |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.79 |
Free Cash Flow (TTM) Free Cash Flow | $-10.61m |
Cash position | $75.63m |
P/E forward | negative |
Short interest | 2.12% |
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
9 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:
9 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 0.05 0.05 |
100%
100%
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -14 -14 |
11%
11%
|
Net Profit | -17 -17 |
29%
29%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
Head office | United States |
CEO | Wesley Kaupinen |
Founded | 2001 |
Website | palvellatx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.